Setting new standards in information exchange for the pharmaceutical and biotech industry
Transdermal Delivery Solutions Corp. to present breakthrough technology at PODD 2013.
September 13, 2013
PODD attendees will be among the first to learn about a revolutionary spray-on drug delivery system for the treatment of low testosterone. Kenneth Kirby, president and CEO of Transdermal Delivery Solutions Corporation (TDSC), will introduce his patented treatment technology during his talk titled, “Innovations in Transdermal Drug Delivery,” during the noon session on Friday, October 11.
Recently awarded FDA approval for clinical testing, TDSC’s Testagen®TDS provides safe and effective treatment for the approximately 13.8 million men in the United States who suffer from low testosterone levels, which has been linked to common ailments ranging from hypertension to fatigue to low sex drive. Testagen®TDS is expected to revolutionize topical testosterone application because it enables rapid, nearly complete absorption of controlled amounts of testosterone across intact skin. The system is based on a delivery vehicle which mimics physical chemistry of compounds that readily transmigrate the skin and provides faster absorption, lower concentrations left on the skin, and lower cost than current transdermal formulations. The formulation process produces an extremely stable dose-specific and drug-specific formula enabling rapid, safe and efficient transdermal drug delivery.
Testagen® TDS was developed through a proprietary system that measures and calculates the intermolecular attractive and repulsive forces of the drug. The patent features include the conceptual development and process for designing and formulating a unique, balanced transdermal system for a particular drug, in this case Testosterone, including stimulus of cellular activation energy. Because the resulting product is liquid, dosing can be adjusted for individual needs by modifying the number of sprays applied. The rapidly drying ethanol base is expected to greatly diminish or eliminate any danger of transferring testosterone to women or children, a significant health risk from existing gel therapies. It is expected that Testagen® TDS will stand alone as the only product to meaningfully address the health risk of transference with a more convenient, flexible-dosing, easy-to-apply product.
Learn more about Testagen®TDS at the noon session on Friday, October 11, 2013. You can also learn more about TDSC and its revolutionaryresearch at http://www.tdsc.us